Medications for obesity as preventatives: a public and patient safety issue
A new wave of injectable medications for obesity have become available globally, with more medications undergoing clinical trials.1,2 However, recent calls3 including the suggested research plan to consider grading medications for obesity as preventative medications for chronic weight management from the US Preventive Services Task Force (USPSTF) in May 2024 are of great concern. Although this might be a direction for future product development and much needed clinical trials, these calls appear premature and potentially dangerous, as these medications have not been clinically tested or approved for use in people without obesity or type 2 diabetes.
